- Home
- RZLV vs TSHA Comparison
RZLV vs TSHA Comparison
Compare RZLV & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RZLV
- TSHA
- Stock Information
- Founded
- RZLV 2016
- TSHA 2019
- Country
- RZLV United Kingdom
- TSHA United States
- Employees
- RZLV N/A
- TSHA N/A
- Industry
- RZLV
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- RZLV
- TSHA Health Care
- Exchange
- RZLV NYSE
- TSHA Nasdaq
- Market Cap
- RZLV 394.3M
- TSHA 403.7M
- IPO Year
- RZLV N/A
- TSHA 2020
- Fundamental
- Price
- RZLV $2.96
- TSHA $1.85
- Analyst Decision
- RZLV Strong Buy
- TSHA Strong Buy
- Analyst Count
- RZLV 4
- TSHA 8
- Target Price
- RZLV $5.50
- TSHA $6.63
- AVG Volume (30 Days)
- RZLV 13.2M
- TSHA 4.9M
- Earning Date
- RZLV 12-31-2024
- TSHA 11-13-2024
- Dividend Yield
- RZLV N/A
- TSHA N/A
- EPS Growth
- RZLV N/A
- TSHA N/A
- EPS
- RZLV N/A
- TSHA N/A
- Revenue
- RZLV $145,051.00
- TSHA $9,915,000.00
- Revenue This Year
- RZLV N/A
- TSHA N/A
- Revenue Next Year
- RZLV N/A
- TSHA N/A
- P/E Ratio
- RZLV N/A
- TSHA N/A
- Revenue Growth
- RZLV 25.96
- TSHA N/A
- 52 Week Low
- RZLV $1.57
- TSHA $1.19
- 52 Week High
- RZLV $14.50
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- RZLV N/A
- TSHA 38.54
- Support Level
- RZLV N/A
- TSHA $1.80
- Resistance Level
- RZLV N/A
- TSHA $2.72
- Average True Range (ATR)
- RZLV 0.00
- TSHA 0.23
- MACD
- RZLV 0.00
- TSHA -0.10
- Stochastic Oscillator
- RZLV 0.00
- TSHA 3.81
About RZLV REZOLVE AI LTD
Rezolve AI Ltd provides a mobile commerce and engagement platform, underpinned by machine learning, that enables retailers, brands and manufacturers to engage with consumers in a broad range of locations and settings via their mobile devices and personal computers. its platform allows for mobile engagement with merchants using its software to extend their business to consumers' mobile devices and computers in different ways.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.